Unilateral RT produced no contralateral neck failures in N2b oropharyngeal cancer
No contralateral neck recurrences occurred among 43 N2b patients receiving unilateral RT despite frequent high ipsilateral nodal burden.
Tag
oropharynx
Severe sleep-related symptoms tracked with worse survival after oropharyngeal cancer radiotherapy
Severe fatigue, sleep disturbance and drowsiness during oropharyngeal cancer RT were independently associated with substantially worse overall survival.
High-dose prednisone produced transient symptom improvement in radiation-associated lower cranial neuropathy
Prednisone 3 mg/kg improved symptoms in 3 of 5 survivors with late cranial neuropathy, but the benefit disappeared by 6–10 weeks.
Pretrained deep-learning IMPT planning transferred across centres with comparable plan quality
After two days of local configuration, a pretrained model generated oropharyngeal IMPT plans with overall quality comparable to manual planning.
CBCT-measured muscle loss during RT predicted survival in HPV-positive oropharyngeal cancer
Routine treatment CBCT detected skeletal muscle loss that independently tracked worse survival in 337 patients with HPV-positive oropharyngeal cancer.
Deep learning proton plans were clinically accepted for all 78 oropharyngeal patients
All 78 deep learning-generated IMPT plans were clinically accepted, with comparable or lower organ doses than manual benchmark plans.
Submandibular gland transfer reduced salivary-gland dose by 12 Gy during proton therapy
Surgical transfer reduced contralateral submandibular mean dose by approximately 12 Gy during bilateral IMPT without compromising target coverage.
BARitOne will escalate oropharyngeal dose only for MRI-defined non-responders
BARitOne uses on-treatment diffusion MRI to increase gross tumour dose from 65 to 73 Gy only in predicted non-responders.
FDG-PET-guided dose escalation did not improve control in advanced oropharyngeal and laryngopharyngeal cancers
Escalating metabolically active disease to 73.5 Gy did not improve locoregional control, disease-free survival, or overall survival versus 66 Gy.
Planning computed tomography radiomics predicted recurrence in human papillomavirus-positive oropharyngeal cancer
A multi-regional clinical-radiomics model reached an external-test area under the curve of 0.908 for 5-year recurrence prediction.
No isolated failures in omitted nodal regions with reduced elective irradiation for early oropharyngeal cancer
Definitive intensity-modulated radiotherapy alone achieved 93.0% three-year overall survival, with no recurrence solely within omitted prophylactic nodal regions.
Mid-treatment tumour shrinkage predicted survival in oropharyngeal cancer
Tumour volume reduction above 40% during radiotherapy was independently associated with improved overall survival in patients with oropharyngeal cancer.
Dose de-escalation improved patient-reported outcomes in early p16-positive oropharyngeal cancer
Reducing radiotherapy from 70 Gy to 60 Gy was associated with better one-year swallowing outcomes and lower acute toxicity in selected patients.
Concurrent chemotherapy improved progression-free but not overall survival in low-volume head and neck cancer
Concurrent chemotherapy improved progression-free survival without a significant overall survival benefit in early primary tumors with low-volume nodal disease.